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Is it Predictive, Punitive, or Protective?*Leslee J. Shaw, PHD,y Jagat Narula, MD, PHD,z Y. Chandrashekhar, MDxH igh-risk atherosclerotic plaques are patho-logically characterized by a thin ﬁbrouscap and substantial plaque burden with a
large necrotic core, intense macrophage inﬁltration,
and spotty calciﬁcation (1–5). Multiple invasive imag-
ing modalities can reliably identify these markers but
their ability to predict long-term outcomes has been
rather modest (2,6). Noninvasive imaging modalities,
such as computed tomography (CT), have been used
to identify many of these high-risk plaque features
(7) and reveal that coronary artery calciﬁcation
(CAC) is one of the strongest predictors of future car-
diac events (8). However, few studies have related
CAC on CT to coronary plaque volume. Importantly,
progression of CAC and overall plaque volume has
potent adverse consequences (9). Furthermore, a
reduction in plaque and necrotic core volume during
therapy is often associated with plaque stabilization
and improved outcomes, but less data are available
regarding CAC in this regard. It is unknown if changes
in CAC track alterations in plaque volume over
time, especially following intercurrent aggressive
risk factor control as a part of guideline-directed pre-
ventive therapy. It has long been speculated that
although microcalciﬁcation and spotty calciﬁcation
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stage of atherosclerosis and the process of calciﬁca-
tion occurs as a stabilizing force in the setting of
high-risk atherosclerotic plaque characterized as
echolucent or low attenuation (7). CAC may thus
have implications that are different from the prog-
nostic import of plaque volume itself.
CAC AND STATINS AND EVENTS
Multiple observations suggest that statin therapy,
which markedly reduces overall cardiovascular
events, seems to increase atherosclerotic plaque
density and CAC scores on CT (1). In 1 trial substudy,
CAC progression was greater in frequent versus less
frequent statin users (8.2  0.5 mm3 vs. 4.2  1.1 mm3;
p < 0.01) (2). It is, however, unclear if statins actively
aid in plaquemineralization or if it is the inﬂammatory
cell death within the lipid core that adds to the overall
volume of calciﬁed plaque and an increase in the
overall CAC score (1). Beyond observations, several
randomized clinical trials revealed that statin therapy
did not attenuate CAC plaque progression (3). These
small, intermediate outcome trials have numerous
limitations but also have a consistent message.
Regression or attenuation of calciﬁed plaque has not
been reported within the rigors of a clinical trial.SEE PAGE 1273In this issue of the Journal, Puri et al. (10) report on
serial changes in coronary atheroma using intravas-
cular ultrasound (IVUS) from 8 pooled clinical trials
following high-dose, low-dose, or no-statin therapy.
Importantly, these pooled results allow for an exam-
ination of a decidedly larger sample of 3,495 patients,
including 1,545 patients receiving high-intensity
statin therapy (HIST) and 1,726 patients receiving
low-intensity statin therapy (LIST), and a limited
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1284sample of patients (n ¼ 224) receiving no lipid-
lowering treatment. One may argue against the
legitimacy of combining these disparate trials with
varying aims, statin doses, and patient populations;
despite the use of weighted propensity scoring tech-
niques. It is also obvious that IVUS, although used for
this purpose in other studies, may not be the optimal
technique for quantifying CAC. Yet, the presented
ﬁndings are intriguing, possibly important in por-
traying CAC in a new light and certainly worthy of
further discussion or even debate. These authors re-
ported that HIST elicited a marked reduction in
percent atheroma volume (p < 0.0001), as has been
consistently reported, whereas lesser doses of statin
or no-statin therapy allowed progression of atheroma
volume. Interestingly, the calculation of an IVUS
calcium index revealed provocative ﬁndings: a sig-
niﬁcant increase in the calcium index following statin
therapy (both HIST [þ0.044] and LIST [þ0.038]) far
greater than that reported for the 224 patients not on
statins (þ0.02). HIST had greater progression in
calciﬁcation as compared with LIST (when both were
compared with the small, no treatment group) that
did not reach signiﬁcance between the statin groups.
There was, thus, a clear interplay between changes in
plaque volumes (and potentially events) and the
change in CAC. CAC seemed to progress independent
of change in plaque regression or progression and was
greater with statin use. These ﬁndings partly support
what many have posited but without deﬁnitive
evidence.
These somewhat controversial ﬁndings may ﬁnd
support from other recent work that reported disso-
ciation between the CAC score and events under
certain conditions. The Multi-Ethnic Study of Athero-
sclerosis found that more dense plaque in the setting
of more extensive CAC scores were observationally
associated with a reduced hazard for cardiovascular
events (5). It gets even more fascinating! If CAC pro-
gression is associated with higher event risk over time,
its dissociation from changes in plaque volume and
events post-therapy raise important questions. CAC
may not be a monolithic unit, as is commonly
conceived, and patterns of CAC (e.g., spotty calciﬁca-
tion vs. more coalesced calciﬁcation) or its density
may have different meanings than 1 lone number (the
Agatston CAC score). It is well-substantiated that risk
factors account for only a small proportion of CAC risk,
and control of risk factors do not seem to signiﬁcantly
impact differences in CAC. The more recent Heinz
Nixdorf Recall registry suggests that CAC progression
is inevitable and predictable based on age and baseline
CAC alone and is unaffected by the burden of risk
factors (11). It might thus appear that the merit of CACin predicting events is largely contained in its presence
and progression (12). More importantly, as a corollary,
the CAC score or its progression might not be as pre-
dictive once plaque-altering treatment is initiated
(e.g., statins). In this latter setting, treatment that
changes plaque volume and impacts on event occur-
rence seems to oppose the directionality of changes in
the CAC score or extent. These ﬁndings should prompt
another look into whether the strong relationship
between CAC progression and events stands intact
during adequate statin therapy. Similarly, how much
of the predicted risk associated with CAC scores
(a score that is rather insensitive to modulation) is
contained in the risk of the extent of coronary plaque
(which is a modiﬁable parameter) is moot. At least
among symptomatic patients in the Coronary CTA
Evaluation For Clinical Outcomes: An International
Multicenter Registry, plaque distribution and extent
robustly predicted all-cause mortality and myocardial
infarction, even after adjusting for CAC (13). One
message from the study by Puri et al.(10) is that if CAC
is reﬂecting the risk solely of plaque volume, the risk
relationship may not remain as robust once plaque is
modiﬁed. It is possible that once risk is detected with
CAC, an attenuation of CAC progression may not be a
useful goal of therapy, but a reduction in events
should certainly be the primary focus. This explains
the negative clinical trials that failed to achieve their
primary endpoint of attenuating CAC progression
following intercurrent statin use (3). A failure to
measure coexisting noncalciﬁed plaque burden and
other high-risk atherosclerotic plaque features within
prior CAC trials may have led to the fatal ﬂaw and
negative trial ﬁndings.
Importantly, we should only consider the current
results as hypothesis-generating, even though they
are intriguing. They cannot infer causality and the
degree to which baseline clinical factors promote
calciﬁcation is unknown. The IVUS calciﬁcation index
has multiple limitations including the fact that
severely calciﬁed plaques were excluded. The index
is very likely a poor quantitative or comparative
measure when compared with CT methods; it might,
however, have some validity in predicting directional
change (vs. magnitudinal alterations), because the
same index was applied serially in this pooled anal-
ysis. Certainly, this report is worthy of additional
investigation.
What are possible future avenues of inquiry?
Further investigation is warranted as to whether
calciﬁcation within the coronary arteries can be seen
as protective and a sign of blocking further progres-
sion of high-risk, low-density plaque. Preclinical
research is revealing complex biochemical pathways
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1285(e.g., those switching on osteoblast transcription
factors, such as Runx2, in vascular smooth muscle
cells) that can be modulated to attenuate or even
promote vascular mineralization as needed (14).
Knowing what CAC means within the context of pla-
que alterations will be important. These results (4)
would also suggest, as others have postulated, that
the effectiveness of risk stratiﬁcation is based on the
concept that CAC is a bystander of coexisting high-
risk atherosclerotic plaque and that variable compo-
nents (i.e., density and volume) (5) of the CAC score
may be more or less critical components of cardiac
event risk. This remains a never-ending story that is
incompletely deﬁned but vital to addressing the
detection gap for atherosclerotic disease. Identiﬁca-
tion of the vulnerable patient remains elusive andwithout established treatment targeted to known
atherosclerotic disease pathways that would lead to
effective risk reduction. We are still left with the most
important question: Although CAC predicts risk, is it
via an intrinsic property of CAC or by being a marker
of high-risk plaque that coronary artery mineraliza-
tion is trying to stabilize? For CAC, paraphrasing
Hamlet’s speech, “To be or not to be” and “Whether tis
nobler. to suffer CAC or to take arms against its sea of
troubles,” still remains a crucial but as yet unan-
swered question.
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